Singular Genomics Systems Inc
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. It is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection wit… Read more
Singular Genomics Systems Inc (OMIC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -0.161x
Based on the latest financial reports, Singular Genomics Systems Inc (OMIC) has a cash flow conversion efficiency ratio of -0.161x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.79 Million) by net assets ($123.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Singular Genomics Systems Inc - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Singular Genomics Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Singular Genomics Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Singular Genomics Systems Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DLH Holdings Corp
NASDAQ:DLHC
|
-0.043x |
|
INSTAL KRAKÓW SA
WAR:INK
|
0.049x |
|
EMBARK EDUCATION LTD.
F:9EV
|
N/A |
|
Alarko Carrier Sanayi ve Ticaret AS
IS:ALCAR
|
-0.001x |
|
Fortune Rise Acquisition Corp
NASDAQ:FRLA
|
-0.009x |
|
Capital & Regional Plc
PINK:CRPLF
|
0.039x |
|
Mobile Appliance Inc.
KQ:087260
|
-0.048x |
|
Pinago Utama Tbk Pt
JK:PNGO
|
0.052x |
Annual Cash Flow Conversion Efficiency for Singular Genomics Systems Inc (2019–2023)
The table below shows the annual cash flow conversion efficiency of Singular Genomics Systems Inc from 2019 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $179.01 Million | $-73.65 Million | -0.411x | -22.97% |
| 2022-12-31 | $260.32 Million | $-87.09 Million | -0.335x | -117.54% |
| 2021-12-31 | $336.17 Million | $-51.70 Million | -0.154x | -131.88% |
| 2020-12-31 | $-51.55 Million | $-24.87 Million | 0.482x | +4.65% |
| 2019-12-31 | $-24.73 Million | $-11.40 Million | 0.461x | -- |